Rivus posts a win for its ex­per­i­men­tal obe­si­ty drug in heart fail­ure pa­tients

Rivus Phar­ma­ceu­ti­cals’ ex­per­i­men­tal car­diometa­bol­ic drug, HU6, nailed a mid-stage tri­al in obese pa­tients with heart fail­ure, find­ing that pa­tients notched a sta­tis­ti­cal­ly sig­nif­i­cant re­duc­tion in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER